Dr. Lili Peng is currently the Head of Analytics in Biogen’s External Innovation unit, in which she is currently applying advanced analytics and AI/ML capabilities to enable external innovation for expanding Biogen’s drug portfolio. Formerly a technology consultant at Booz Allen Hamilton, she has experience in data science, data management, and software implementation projects at the U. S. Food and Drug Administration. Prior to that, she worked as an informatics scientist at AstraZeneca providing informatics, analytics, and programmatics solutions in research and development, medical affairs, and medical evidence and observational research. Lili completed her postdoctoral training in computational chemistry and bioinformatics, respectively, at University of California, San Francisco and Stanford University. Prior to that, she did her Ph.D. in bioengineering from the University of California, San Diego in computational modeling of an anticancer polymeric drug delivery system. She holds a B.S. in chemical engineering from the Massachusetts Institute of Technology.